Compare Citius Pharmaceuticals Inc (CTXR) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Raytheon Technologies Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Raytheon Technologies Corp trades at $184.94 (market cap $242.95B). The key difference: Raytheon Technologies Corp is far larger — about 17617.8× Citius Pharmaceuticals Inc's market cap, and Raytheon Technologies Corp pays a 1.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Raytheon Technologies Corp for 78 Days on average.
| CTXR | RTX | |
|---|---|---|
Market Cap | $13.79M | $242.95B |
Volume | 156,684 | 4,213,378 |
Sector | Health | Industrials |
52-Week High | $1.82 | $225.49 |
52-Week Low | $0.48 | $157.00 |
Typical Hold Time | 16 Days | 78 Days |
Enterprise Value | $3.96M | $273.50B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
RTX trades at $184.32, up 0.56% today, with strong fundamental momentum as revenue grew to $88.6B in 2025 and net income reached $6.73B. The company has beaten earnings estimates for three consecutive quarters, supported by a massive $289B backlog. Technical indicators show a bearish short-term trend despite bullish oscillators, while analyst consensus remains strongly positive with a $237.60 price target.
RTX presents a compelling investment case with robust defense sector tailwinds and consistent earnings outperformance. Key risks include execution challenges in managing the large backlog and potential defense budget volatility. The stock offers 29% upside to consensus targets, making it attractive for long-term investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
